US20050025763A1 - Therapeutic use of anti-CS1 antibodies - Google Patents

Therapeutic use of anti-CS1 antibodies Download PDF

Info

Publication number
US20050025763A1
US20050025763A1 US10/842,011 US84201104A US2005025763A1 US 20050025763 A1 US20050025763 A1 US 20050025763A1 US 84201104 A US84201104 A US 84201104A US 2005025763 A1 US2005025763 A1 US 2005025763A1
Authority
US
United States
Prior art keywords
antibody
cells
antibodies
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/842,011
Other languages
English (en)
Inventor
Marna Williams
J. Tso
Nicholas Landolfi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
AbbVie Biotherapeutics Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Priority to US10/842,011 priority Critical patent/US20050025763A1/en
Assigned to PROTEIN DESIGN LABS, INC. reassignment PROTEIN DESIGN LABS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TSO, J. YUN, WILLIAMS, MARNA, LANDOLFI, NICHOLAS F.
Priority to US10/982,357 priority patent/US7709610B2/en
Priority to PL10180748T priority patent/PL2301576T3/pl
Priority to AU2004318675A priority patent/AU2004318675B2/en
Priority to DE602004029399T priority patent/DE602004029399D1/de
Priority to EP04810631A priority patent/EP1729803B1/en
Priority to PT101807485T priority patent/PT2301576E/pt
Priority to BRPI0418695-8A priority patent/BRPI0418695A/pt
Priority to EP10180748A priority patent/EP2301576B1/en
Priority to DK10180748.5T priority patent/DK2301576T3/da
Priority to JP2007506135A priority patent/JP4758984B2/ja
Priority to PCT/US2004/037430 priority patent/WO2005102387A2/en
Priority to CA002561065A priority patent/CA2561065A1/en
Priority to SI200431948T priority patent/SI2301576T1/sl
Priority to ES10180748T priority patent/ES2393539T3/es
Priority to CN2004800431539A priority patent/CN1960750B/zh
Priority to AT04810631T priority patent/ATE482722T1/de
Priority to KR1020067022536A priority patent/KR101146775B1/ko
Priority to MXPA06011241A priority patent/MXPA06011241A/es
Publication of US20050025763A1 publication Critical patent/US20050025763A1/en
Assigned to PDL BIOPHARMA, INC. reassignment PDL BIOPHARMA, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: PROTEIN DESIGN LABS, INC.
Priority to IL178121A priority patent/IL178121A/en
Priority to HK07107070.1A priority patent/HK1099699A1/xx
Assigned to FACET BIOTECH CORPORATION reassignment FACET BIOTECH CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PDL BIOPHARMA, INC.
Priority to US12/397,026 priority patent/US8088898B2/en
Priority to US12/401,531 priority patent/US20090238827A1/en
Priority to US12/401,513 priority patent/US8133981B2/en
Assigned to PDL BIOPHARMA reassignment PDL BIOPHARMA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LIU, GAO
Assigned to FACET BIOTECH CORPORATION reassignment FACET BIOTECH CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PDL BIOPHARMA, INC.
Priority to US12/610,899 priority patent/US8008450B2/en
Priority to AU2011200999A priority patent/AU2011200999B2/en
Priority to US13/174,134 priority patent/US8445646B2/en
Priority to US13/175,733 priority patent/US8349330B2/en
Priority to US13/175,751 priority patent/US8461306B2/en
Priority to US13/175,748 priority patent/US8444980B2/en
Priority to US13/175,759 priority patent/US8436146B2/en
Priority to HK11110054.9A priority patent/HK1155670A1/xx
Priority to HRP20120975TT priority patent/HRP20120975T1/hr
Priority to CY20121101174T priority patent/CY1115003T1/el
Assigned to ABBVIE BIOTHERAPEUTICS INC. reassignment ABBVIE BIOTHERAPEUTICS INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ABBOTT BIOTHERAPEUTICS CORP.
Priority to US13/894,857 priority patent/US9175081B2/en
Priority to US14/860,906 priority patent/US10442859B2/en
Priority to IL243687A priority patent/IL243687A0/en
Priority to US16/599,035 priority patent/US20200031929A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
US10/842,011 2003-05-08 2004-05-07 Therapeutic use of anti-CS1 antibodies Abandoned US20050025763A1 (en)

Priority Applications (38)

Application Number Priority Date Filing Date Title
US10/842,011 US20050025763A1 (en) 2003-05-08 2004-05-07 Therapeutic use of anti-CS1 antibodies
US10/982,357 US7709610B2 (en) 2003-05-08 2004-11-05 Therapeutic use of anti-CS1 antibodies
JP2007506135A JP4758984B2 (ja) 2004-03-29 2004-11-08 抗ｃｓ１抗体の治療的使用
MXPA06011241A MXPA06011241A (es) 2004-03-29 2004-11-08 Uso terapeutico de anticuerpos anti-csi.
SI200431948T SI2301576T1 (sl) 2004-03-29 2004-11-08 Terapevtska uporaba protiteles proti CS1
DE602004029399T DE602004029399D1 (es) 2004-03-29 2004-11-08
EP04810631A EP1729803B1 (en) 2004-03-29 2004-11-08 Therapeutic use of anti-cs1 antibodies
PT101807485T PT2301576E (pt) 2004-03-29 2004-11-08 Utilização terapêutica de anticorpos anti-cs1
BRPI0418695-8A BRPI0418695A (pt) 2004-03-29 2004-11-08 uso terapêutico de anticorpos anti-cs1
EP10180748A EP2301576B1 (en) 2004-03-29 2004-11-08 Therapeutic use of Anti-CS1 Antibodies
DK10180748.5T DK2301576T3 (da) 2004-03-29 2004-11-08 Terapeutisk anvendelse af anti-CS1-antistoffer
PL10180748T PL2301576T3 (pl) 2004-03-29 2004-11-08 Zastosowanie terapeutyczne przeciwciał anty-CS1
PCT/US2004/037430 WO2005102387A2 (en) 2004-03-29 2004-11-08 Therapeutic use of anti-cs1 antibodies
CA002561065A CA2561065A1 (en) 2004-03-29 2004-11-08 Therapeutic use of anti-cs1 antibodies
AU2004318675A AU2004318675B2 (en) 2004-03-29 2004-11-08 Therapeutic use of anti-CS1 antibodies
ES10180748T ES2393539T3 (es) 2004-03-29 2004-11-08 Utilización terapéutica de anticuerpos anti-CS1
CN2004800431539A CN1960750B (zh) 2004-03-29 2004-11-08 抗cs1抗体的治疗用途
AT04810631T ATE482722T1 (de) 2004-03-29 2004-11-08 Therapeutische verwendung von anti-cs1- antikörpern
KR1020067022536A KR101146775B1 (ko) 2004-03-29 2004-11-08 항-ｃｓ1 항체의 치료적 용도
IL178121A IL178121A (en) 2004-03-29 2006-09-14 Anti-cs-1 antibodies for the treatment of multiple myeloma
HK07107070.1A HK1099699A1 (en) 2004-03-29 2007-07-03 Therapeutic use of anti-cs1 antibodies
US12/397,026 US8088898B2 (en) 2003-05-08 2009-03-03 Therapeutic use of anti-CS1 antibodies
US12/401,531 US20090238827A1 (en) 2003-05-08 2009-03-10 Therapeutic use of anti-cs1 antibodies
US12/401,513 US8133981B2 (en) 2003-05-08 2009-03-10 Therapeutic use of anti-CS1 antibodies
US12/610,899 US8008450B2 (en) 2003-05-08 2009-11-02 Therapeutic use of anti-CS1 antibodies
AU2011200999A AU2011200999B2 (en) 2004-03-29 2011-03-07 Therapeutic use of anti-CS1 antibodies
US13/174,134 US8445646B2 (en) 2003-05-08 2011-06-30 Therapeutic use of anti-CS1 antibodies
US13/175,733 US8349330B2 (en) 2003-05-08 2011-07-01 Therapeutic use of anti-CS1 antibodies
US13/175,751 US8461306B2 (en) 2003-05-08 2011-07-01 Therapeutic use of anti-CS1 antibodies
US13/175,748 US8444980B2 (en) 2003-05-08 2011-07-01 Therapeutic use of anti-CS1 antibodies
US13/175,759 US8436146B2 (en) 2003-05-08 2011-07-01 Therapeutic use of anti-CS1 antibodies
HK11110054.9A HK1155670A1 (en) 2004-03-29 2011-09-23 Therapeutic use of anti-cs1 antibodies
HRP20120975TT HRP20120975T1 (hr) 2004-03-29 2012-11-28 Terapeutska upotreba anti-cs1 antitijela
CY20121101174T CY1115003T1 (el) 2004-03-29 2012-11-30 Θεραπευτικη χρηση των αντισωματων αντι-cs1
US13/894,857 US9175081B2 (en) 2003-05-08 2013-05-15 Therapeutic use of anti-CS1 antibodies
US14/860,906 US10442859B2 (en) 2003-05-08 2015-09-22 Therapeutic use of anti-CS1 antibodies
IL243687A IL243687A0 (en) 2004-03-29 2016-01-19 For the treatment of multiple myeloma 1–cs antibodies against
US16/599,035 US20200031929A1 (en) 2003-05-08 2019-10-10 Therapeutic use of anti-cs1 antibodies

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46921103P 2003-05-08 2003-05-08
US55762104P 2004-03-29 2004-03-29
US55762204P 2004-03-29 2004-03-29
US55762004P 2004-03-29 2004-03-29
US10/842,011 US20050025763A1 (en) 2003-05-08 2004-05-07 Therapeutic use of anti-CS1 antibodies

Related Child Applications (5)

Application Number Title Priority Date Filing Date
US10/982,357 Continuation-In-Part US7709610B2 (en) 2003-05-08 2004-11-05 Therapeutic use of anti-CS1 antibodies
US10/982,357 Continuation US7709610B2 (en) 2003-05-08 2004-11-05 Therapeutic use of anti-CS1 antibodies
US12/401,531 Division US20090238827A1 (en) 2003-05-08 2009-03-10 Therapeutic use of anti-cs1 antibodies
US12/401,513 Continuation US8133981B2 (en) 2003-05-08 2009-03-10 Therapeutic use of anti-CS1 antibodies
US12/610,899 Continuation US8008450B2 (en) 2003-05-08 2009-11-02 Therapeutic use of anti-CS1 antibodies

Publications (1)

Publication Number Publication Date
US20050025763A1 true US20050025763A1 (en) 2005-02-03

Family

ID=33459144

Family Applications (8)

Application Number Title Priority Date Filing Date
US10/842,011 Abandoned US20050025763A1 (en) 2003-05-08 2004-05-07 Therapeutic use of anti-CS1 antibodies
US12/401,531 Abandoned US20090238827A1 (en) 2003-05-08 2009-03-10 Therapeutic use of anti-cs1 antibodies
US12/401,513 Active 2024-05-20 US8133981B2 (en) 2003-05-08 2009-03-10 Therapeutic use of anti-CS1 antibodies
US12/610,899 Expired - Lifetime US8008450B2 (en) 2003-05-08 2009-11-02 Therapeutic use of anti-CS1 antibodies
US13/174,134 Expired - Lifetime US8445646B2 (en) 2003-05-08 2011-06-30 Therapeutic use of anti-CS1 antibodies
US13/894,857 Expired - Lifetime US9175081B2 (en) 2003-05-08 2013-05-15 Therapeutic use of anti-CS1 antibodies
US14/860,906 Active 2025-08-19 US10442859B2 (en) 2003-05-08 2015-09-22 Therapeutic use of anti-CS1 antibodies
US16/599,035 Abandoned US20200031929A1 (en) 2003-05-08 2019-10-10 Therapeutic use of anti-cs1 antibodies

Family Applications After (7)

Application Number Title Priority Date Filing Date
US12/401,531 Abandoned US20090238827A1 (en) 2003-05-08 2009-03-10 Therapeutic use of anti-cs1 antibodies
US12/401,513 Active 2024-05-20 US8133981B2 (en) 2003-05-08 2009-03-10 Therapeutic use of anti-CS1 antibodies
US12/610,899 Expired - Lifetime US8008450B2 (en) 2003-05-08 2009-11-02 Therapeutic use of anti-CS1 antibodies
US13/174,134 Expired - Lifetime US8445646B2 (en) 2003-05-08 2011-06-30 Therapeutic use of anti-CS1 antibodies
US13/894,857 Expired - Lifetime US9175081B2 (en) 2003-05-08 2013-05-15 Therapeutic use of anti-CS1 antibodies
US14/860,906 Active 2025-08-19 US10442859B2 (en) 2003-05-08 2015-09-22 Therapeutic use of anti-CS1 antibodies
US16/599,035 Abandoned US20200031929A1 (en) 2003-05-08 2019-10-10 Therapeutic use of anti-cs1 antibodies

Country Status (25)

Country Link
US (8) US20050025763A1 (es)
EP (4) EP2371391B1 (es)
JP (4) JP4887152B2 (es)
KR (1) KR101268707B1 (es)
CN (1) CN1805755B (es)
AT (1) ATE506076T1 (es)
AU (2) AU2004238363B2 (es)
BE (1) BE2016C056I2 (es)
BR (1) BRPI0410129B8 (es)
CA (1) CA2523001C (es)
CY (4) CY1111958T1 (es)
DE (1) DE602004032328D1 (es)
DK (3) DK2371391T3 (es)
ES (2) ES2516840T3 (es)
FR (1) FR16C1012I2 (es)
HK (3) HK1089374A1 (es)
HU (2) HUE034908T2 (es)
LT (1) LT2853272T (es)
LU (1) LU93274I2 (es)
MX (1) MXPA05012011A (es)
NL (1) NL300838I2 (es)
PL (3) PL1624892T3 (es)
PT (3) PT2853272T (es)
SI (3) SI2853272T1 (es)
WO (1) WO2004100898A2 (es)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008019376A2 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
WO2008019378A1 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
US20080095768A1 (en) * 2006-08-07 2008-04-24 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
WO2010080910A1 (en) * 2009-01-08 2010-07-15 Bio-Rad Laboratories, Inc. Methods and compositions for improving efficiency of nucleic acids amplification reactions
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
US20110200585A1 (en) * 2010-01-28 2011-08-18 Ian Kirby Cd127 binding proteins
US20110206701A1 (en) * 2008-10-31 2011-08-25 Daniel Afar Use of anti-cs1 antibodies for treatment of rare lymphomas
WO2011106528A1 (en) * 2010-02-24 2011-09-01 Immunogen, Inc. Folate receptor 1 antibodies and immunoconjugates and uses thereof
US8445646B2 (en) 2003-05-08 2013-05-21 Abbvie Biotherapeutics Inc. Therapeutic use of anti-CS1 antibodies
US8709432B2 (en) 2011-04-01 2014-04-29 Immunogen, Inc. Methods for increasing efficacy of FOLR1 cancer therapy
US9200073B2 (en) 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
WO2016168766A1 (en) * 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized chimeric receptor t cell switches and uses thereof
US9637547B2 (en) 2013-08-30 2017-05-02 Immunogen, Inc. Monoclonal antibodies for detection of folate receptor 1
WO2017079115A1 (en) * 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding tim-3 and their uses
US20170292127A1 (en) * 2014-09-23 2017-10-12 Board of Trustee of Michigan State University Compositions and methods for modulating an immune response
US20180029631A1 (en) * 2015-02-16 2018-02-01 Robert Bosch Automotive Steering Gmbh Intermediate Steering Shaft for a Motor Vehicle, and Method for Operating an Intermediate Steering Shaft for a Motor Vehicle
US20180258168A1 (en) * 2017-03-13 2018-09-13 Intrinsic Lifesciences Llc Antibodies to human erythroferrone and uses thereof
US10172875B2 (en) 2015-09-17 2019-01-08 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
WO2020002579A1 (en) 2018-06-29 2020-01-02 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Tweak-receptor agonists for use in combination with immunotherapy of a cancer
WO2021092044A1 (en) 2019-11-05 2021-05-14 Bristol-Myers Squibb Company M-protein assays and uses thereof
WO2021158660A3 (en) * 2020-02-05 2021-09-23 Navaux, Inc. Anti-hepsin antibodies and uses thereof
US11209082B2 (en) 2013-10-14 2021-12-28 Club Car, Llc Self-preloading shift lever
US11845794B2 (en) * 2013-05-03 2023-12-19 Ohio State Innovation Foundation CS1-specific chimeric antigen receptor engineered immune effector cells

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US9096681B2 (en) * 2008-06-02 2015-08-04 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
EP2970436B1 (en) * 2013-03-15 2018-09-05 AbbVie Biotherapeutics Inc. Fc variants
EP3216804A3 (en) * 2013-03-15 2017-12-20 AbbVie Biotechnology Ltd. Anti-cd25 antibodies and their uses
WO2015013508A2 (en) * 2013-07-24 2015-01-29 The General Hospital Corporation Methods for diagnosing and treating immune disease
WO2015069785A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
US20160264670A1 (en) 2013-11-06 2016-09-15 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
CA2947646A1 (en) * 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
ME03678B (me) * 2014-06-17 2020-10-20 Univ California Unapređena alfa-v beta-8 antitela
WO2016011210A2 (en) 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
AU2015339012B2 (en) 2014-10-31 2020-11-05 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
EA201791049A1 (ru) 2014-12-04 2017-10-31 Бристол-Майерс Сквибб Компани Комбинация анти-cs1 и анти-pd1 антител для лечения рака (миеломы)
AU2016219785B2 (en) 2015-02-20 2021-10-28 Ohio State Innovation Foundation Bivalent antibody directed against NKG2D and tumor associated antigens
ES2886657T3 (es) 2015-06-29 2021-12-20 Bristol Myers Squibb Co Regímenes de dosificación inmunoterapéutica que comprenden pomalidomida y un anticuerpo anti-CS1 para el tratamiento de cáncer
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
EP3601365A4 (en) 2017-03-29 2021-01-13 Agency for Science, Technology and Research ANTI-OLIGOSACCHARIDE ANTIBODIES
PL3538645T3 (pl) 2017-06-20 2021-11-08 Institut Curie Komórki odpornościowe z defektem suv39h1
SG11202000846WA (en) * 2017-08-07 2020-02-27 Nbe Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
CN111902159A (zh) 2017-11-01 2020-11-06 朱诺治疗学股份有限公司 对b细胞成熟抗原（bcma）具有特异性的嵌合抗原受体
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
US11623961B2 (en) 2017-11-01 2023-04-11 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
US20210254000A1 (en) 2017-11-01 2021-08-19 Juno Therapeutics, Inc. Process for producing a t cell composition
BR112020008340A2 (pt) 2017-11-01 2020-11-17 Juno Therapeutics Inc processo para gerar composições terapêuticas de células modificadas
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
SG11202005272SA (en) 2017-12-08 2020-07-29 Juno Therapeutics Inc Process for producing a composition of engineered t cells
US20210128616A1 (en) 2017-12-08 2021-05-06 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
WO2019113556A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
JOP20200215A1 (ar) 2018-03-05 2020-09-03 Janssen Pharmaceutica Nv الأجسام المضادة لـ PHF-Tau المضاد واستخداماتها
AU2019316647A1 (en) 2018-08-09 2021-02-25 Juno Therapeutics, Inc. Methods for assessing integrated nucleic acids
CN109406798A (zh) * 2018-10-29 2019-03-01 美康生物科技股份有限公司 肌酐酶法检测试剂盒
EP3873943A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
AU2019374103A1 (en) 2018-11-01 2021-05-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
IL263394A (en) * 2018-11-29 2020-05-31 Amit Ido Methods for activating inactive immune cells and cancer treatment
AU2020265741A1 (en) 2019-05-01 2021-11-25 Editas Medicine, Inc. Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
KR20220016474A (ko) 2019-05-01 2022-02-09 주노 쎄러퓨티크스 인코퍼레이티드 변형된 ｃｄ247 유전자 자리로부터 키메라 수용체를 발현하는 세포, 관련 폴리뉴클레오타이드 및 방법
WO2021013950A1 (en) 2019-07-23 2021-01-28 Mnemo Therapeutics Immune cells defective for suv39h1
AU2021251265A1 (en) 2020-04-10 2022-11-03 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
WO2021231657A1 (en) 2020-05-13 2021-11-18 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
EP4171616A1 (en) 2020-06-26 2023-05-03 Juno Therapeutics GmbH Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
EP4188395A1 (en) 2020-07-30 2023-06-07 Institut Curie Immune cells defective for socs1
CN116802203A (zh) 2020-11-04 2023-09-22 朱诺治疗学股份有限公司 从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法
JP2024509853A (ja) 2021-03-03 2024-03-05 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法およびｄｇｋ阻害剤の組合せ
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
WO2022238386A1 (en) 2021-05-10 2022-11-17 Institut Curie Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
WO2022248602A1 (en) 2021-05-25 2022-12-01 Institut Curie Myeloid cells overexpressing bcl2
WO2023126458A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
WO2023159182A1 (en) 2022-02-18 2023-08-24 Rakuten Medical, Inc. Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
WO2023187024A1 (en) 2022-03-31 2023-10-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020123617A1 (en) * 1999-12-23 2002-09-05 Starling Gary C. Novel immunoglobulin superfamily members of APEX-1, APEX-2 and APEX-3 and uses thereof
US6478825B1 (en) * 2001-11-28 2002-11-12 Osteotech, Inc. Implant, method of making same and use of the implant for the treatment of bone defects
US20030027986A1 (en) * 1998-12-30 2003-02-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
US6607898B1 (en) * 1996-03-26 2003-08-19 Oncomedx, Inc. Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
US7041499B2 (en) * 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5004692A (en) 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
KR0162259B1 (ko) 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
US20020099179A1 (en) * 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
AU6094696A (en) 1995-06-05 1996-12-24 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
WO2003004622A2 (en) 2001-03-21 2003-01-16 Human Genome Sciences, Inc. Human secreted proteins
JP2001522239A (ja) 1997-03-21 2001-11-13 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ８７個のヒト分泌タンパク質
CA2328895A1 (en) 1998-06-02 1999-12-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6020599A (en) 1998-08-25 2000-03-14 Incyte Pharmaceuticals, Inc. Cell surface immunomodulators
JP2002540763A (ja) 1999-02-10 2002-12-03 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ３３個のヒト分泌タンパク質
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
AU3750000A (en) 1999-03-15 2000-10-04 Eos Biotechnology, Inc. Reusable low fluorescent plastic biochip
ATE478145T1 (de) 1999-06-02 2010-09-15 Genentech Inc Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren
EP1208202A2 (en) 1999-09-01 2002-05-29 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001071005A2 (en) * 2000-03-24 2001-09-27 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
JP2003534022A (ja) 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
CA2436092A1 (en) * 2001-01-29 2002-08-08 Idec Pharmaceutical Corporation Modified antibodies and methods of use
AU2002313559A1 (en) 2001-08-23 2003-03-10 Oxford Biomedica (Uk) Limited Genes
US20040038877A1 (en) 2001-10-02 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
KR20110096536A (ko) 2008-10-31 2011-08-30 애보트 바이오테라퓨틱스 코포레이션 희귀 림프종의 치료를 위한 항ｃｓ1 항체의 용도
US9701019B2 (en) 2011-09-15 2017-07-11 Convergent Information Technologies Gmbh System and method for the automatic generation of robot programs
ES2741897T3 (es) 2012-02-13 2020-02-12 Radius Eng Inc Cartucho reutilizable para moldeo por inyección

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607898B1 (en) * 1996-03-26 2003-08-19 Oncomedx, Inc. Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
US20030027986A1 (en) * 1998-12-30 2003-02-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020123617A1 (en) * 1999-12-23 2002-09-05 Starling Gary C. Novel immunoglobulin superfamily members of APEX-1, APEX-2 and APEX-3 and uses thereof
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
US6478825B1 (en) * 2001-11-28 2002-11-12 Osteotech, Inc. Implant, method of making same and use of the implant for the treatment of bone defects
US7041499B2 (en) * 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10442859B2 (en) 2003-05-08 2019-10-15 Abbvie Biotherapeutics Inc. Therapeutic use of anti-CS1 antibodies
US8445646B2 (en) 2003-05-08 2013-05-21 Abbvie Biotherapeutics Inc. Therapeutic use of anti-CS1 antibodies
US9175081B2 (en) 2003-05-08 2015-11-03 Abbvie Biotherapeutics Inc. Therapeutic use of anti-CS1 antibodies
EP2425849A2 (en) 2006-08-07 2012-03-07 Abbott Biotherapeutics Corp. Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
EP3115049A1 (en) 2006-08-07 2017-01-11 AbbVie Biotherapeutics Inc. Combination therapies based on anti-cs1 antibodies for treating multiple myeloma
CN101686971A (zh) * 2006-08-07 2010-03-31 菲赛特生物技术公司 使用基于抗cs1-抗体的联合疗法治疗多发性骨髓瘤的方法
EP2942057A1 (en) 2006-08-07 2015-11-11 AbbVie Biotherapeutics Inc. Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
US7842293B2 (en) 2006-08-07 2010-11-30 Facet Biotech Corporation Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
US20160137735A1 (en) * 2006-08-07 2016-05-19 Abbvie Biotherapeutics Inc. Method of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
US20110165154A1 (en) * 2006-08-07 2011-07-07 Facet Biotech Corporation Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
NO346835B1 (no) * 2006-08-07 2023-01-23 Dana Farber Cancer Inst Inc Anvendelse av anti-CS1 antistoffet HuLuc63 i kombinasjonsbehandlinger for behandling av multippelt myelom
US8632772B2 (en) * 2006-08-07 2014-01-21 Dana-Farber Cancer Institute Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
NO345083B1 (no) * 2006-08-07 2020-09-21 Abbvie Biotherapeutics Inc Humaniserte anti-CS1 Ig G1-antistoffer til bruk for behandling av multippelt myelom, og anvendelse av slike for fremstilling av et medikament for behandling av multippelt myelom.
US20080152646A1 (en) * 2006-08-07 2008-06-26 Dana-Farber Cancer Institute Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
US20080095768A1 (en) * 2006-08-07 2008-04-24 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
EP2425849A3 (en) * 2006-08-07 2012-05-09 Abbott Biotherapeutics Corp. Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
WO2008019376A3 (en) * 2006-08-07 2008-07-10 Pdl Biopharma Inc Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
AU2007281684B2 (en) * 2006-08-07 2013-05-16 Abbvie Biotherapeutics Inc. Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
AU2007281682B2 (en) * 2006-08-07 2013-05-16 Abbvie Biotherapeutics Inc. Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
WO2008019378A1 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
EP2641600A1 (en) 2006-08-07 2013-09-25 AbbVie Biotherapeutics Inc. Methods of Treating Multiple Myeloma Using Combination Therapies based on Anti-CS1 Antibodies
EP2641601A1 (en) 2006-08-07 2013-09-25 AbbVie Biotherapeutics Inc. Methods of treating multiple myeloma using combination therapies based on HuLuc63 with bortezimob
WO2008019376A2 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
AU2007281684C1 (en) * 2006-08-07 2013-12-19 Abbvie Biotherapeutics Inc. Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
US8603477B2 (en) 2008-10-31 2013-12-10 Abbvie Biotherapeutics Inc. Use of anti-CS1 antibodies for treatment of rare lymphomas
US20110206701A1 (en) * 2008-10-31 2011-08-25 Daniel Afar Use of anti-cs1 antibodies for treatment of rare lymphomas
WO2010080910A1 (en) * 2009-01-08 2010-07-15 Bio-Rad Laboratories, Inc. Methods and compositions for improving efficiency of nucleic acids amplification reactions
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
EA023700B1 (ru) * 2010-01-28 2016-07-29 Глаксо Груп Лимитед Cd127-связывающие белки
CN102812046A (zh) * 2010-01-28 2012-12-05 葛兰素集团有限公司 Cd127结合蛋白
US20110200585A1 (en) * 2010-01-28 2011-08-18 Ian Kirby Cd127 binding proteins
US8940303B2 (en) 2010-01-28 2015-01-27 Glaxo Group Limited CD127 binding proteins
WO2011094259A3 (en) * 2010-01-28 2011-09-29 Glaxo Group Limited Cd127 binding proteins
US9150653B2 (en) 2010-01-28 2015-10-06 Glaxo Group Limited CD127 binding proteins
US9598490B2 (en) 2010-02-24 2017-03-21 Immunogen, Inc. Folate receptor 1 antibodies and immunoconjugates and uses thereof
US9133275B2 (en) 2010-02-24 2015-09-15 Immunogen, Inc. Folate receptor 1 antibodies and immunoconjugates and uses thereof
US8557966B2 (en) 2010-02-24 2013-10-15 Immunogen, Inc. Folate receptor 1 antibodies and immunoconjugates and uses thereof
WO2011106528A1 (en) * 2010-02-24 2011-09-01 Immunogen, Inc. Folate receptor 1 antibodies and immunoconjugates and uses thereof
US10752683B2 (en) 2010-02-24 2020-08-25 Immunogen, Inc. Folate receptor 1 antibodies and immunoconjugates and uses thereof
US10301385B2 (en) 2010-02-24 2019-05-28 Immunogen, Inc. Folate receptor 1 antibodies and immunoconjugates and uses thereof
US9657100B2 (en) 2010-02-24 2017-05-23 Immunogen, Inc. Folate receptor 1 antibodies and immunoconjugates and uses thereof
US9670280B2 (en) 2010-02-24 2017-06-06 Immunogen, Inc. Folate receptor 1 antibodies and immunoconjugates and uses thereof
US9670279B2 (en) 2010-02-24 2017-06-06 Immunogen, Inc. Folate receptor 1 antibodies and immunoconjugates and uses thereof
US9670278B2 (en) 2010-02-24 2017-06-06 Immunogen, Inc. Folate receptor 1 antibodies and immunoconjugates and uses thereof
US8709432B2 (en) 2011-04-01 2014-04-29 Immunogen, Inc. Methods for increasing efficacy of FOLR1 cancer therapy
US11135305B2 (en) 2011-04-01 2021-10-05 Immunogen, Inc. Methods for increasing efficacy of FOLR1 cancer therapy
US10613093B2 (en) 2012-08-31 2020-04-07 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
US9702881B2 (en) 2012-08-31 2017-07-11 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
US9200073B2 (en) 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
US10180432B2 (en) 2012-08-31 2019-01-15 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
US11845794B2 (en) * 2013-05-03 2023-12-19 Ohio State Innovation Foundation CS1-specific chimeric antigen receptor engineered immune effector cells
US11932701B2 (en) 2013-08-30 2024-03-19 Immunogen, Inc. Method for increasing the efficacy of cancer therapy by administering an anti-FOLR1 immunoconjugate
US10544230B2 (en) 2013-08-30 2020-01-28 Immunogen, Inc. Methods of using antibodies to detect folate receptor 1 (FOLR1)
US10017578B2 (en) 2013-08-30 2018-07-10 Immunogen, Inc. Methods of treating cancer in a patient by administering anti-folate-receptor-1 (FOLR1) antibodies
US9637547B2 (en) 2013-08-30 2017-05-02 Immunogen, Inc. Monoclonal antibodies for detection of folate receptor 1
US11198736B2 (en) 2013-08-30 2021-12-14 Immunogen, Inc. Method for identifying an ovarian cancer in a subject likely to respond to anti-folate receptor 1 (FOLR1) antibody
US11209082B2 (en) 2013-10-14 2021-12-28 Club Car, Llc Self-preloading shift lever
US10752902B2 (en) * 2014-09-23 2020-08-25 Board Of Trustees Of Michigan State University Compositions comprising fusion proteins useful for modulating an immune response
US20170292127A1 (en) * 2014-09-23 2017-10-12 Board of Trustee of Michigan State University Compositions and methods for modulating an immune response
US20180029631A1 (en) * 2015-02-16 2018-02-01 Robert Bosch Automotive Steering Gmbh Intermediate Steering Shaft for a Motor Vehicle, and Method for Operating an Intermediate Steering Shaft for a Motor Vehicle
WO2016168766A1 (en) * 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized chimeric receptor t cell switches and uses thereof
US10172875B2 (en) 2015-09-17 2019-01-08 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
US11033564B2 (en) 2015-09-17 2021-06-15 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
US10894830B2 (en) 2015-11-03 2021-01-19 Janssen Biotech, Inc. Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
WO2017079115A1 (en) * 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding tim-3 and their uses
US11142572B2 (en) 2017-03-13 2021-10-12 Intrinsic Lifesciences Llc Antibodies to human erythroferrone and uses thereof
US10604567B2 (en) * 2017-03-13 2020-03-31 Intrinsic Lifesciences Llc Antibodies to human erythroferrone and uses thereof
US20180258168A1 (en) * 2017-03-13 2018-09-13 Intrinsic Lifesciences Llc Antibodies to human erythroferrone and uses thereof
WO2020002579A1 (en) 2018-06-29 2020-01-02 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Tweak-receptor agonists for use in combination with immunotherapy of a cancer
WO2021092044A1 (en) 2019-11-05 2021-05-14 Bristol-Myers Squibb Company M-protein assays and uses thereof
WO2021158660A3 (en) * 2020-02-05 2021-09-23 Navaux, Inc. Anti-hepsin antibodies and uses thereof

Also Published As

Publication number Publication date
ES2516840T3 (es) 2014-10-31
CY2016035I1 (el) 2017-09-13
HUE034908T2 (hu) 2018-03-28
EP1624892A4 (en) 2007-08-08
US20100168397A1 (en) 2010-07-01
PL2853272T3 (pl) 2018-01-31
CA2523001A1 (en) 2004-11-25
US20140065063A1 (en) 2014-03-06
SI2853272T1 (sl) 2017-10-30
ATE506076T1 (de) 2011-05-15
HK1089374A1 (en) 2006-12-01
HUS1600042I1 (hu) 2016-11-28
JP6042834B2 (ja) 2016-12-14
BE2016C056I2 (es) 2023-08-09
BRPI0410129A (pt) 2006-05-16
AU2010214661A1 (en) 2010-09-16
CN1805755B (zh) 2011-06-01
WO2004100898A2 (en) 2004-11-25
CY2016035I2 (el) 2017-09-13
US20120064083A1 (en) 2012-03-15
PT2371391E (pt) 2014-10-30
EP2371391A1 (en) 2011-10-05
EP2371391B1 (en) 2014-07-23
LU93274I2 (fr) 2016-12-27
AU2004238363B2 (en) 2010-05-27
US8445646B2 (en) 2013-05-21
US9175081B2 (en) 2015-11-03
JP2014139187A (ja) 2014-07-31
MXPA05012011A (es) 2006-02-03
BRPI0410129B1 (pt) 2020-02-11
DK2371391T3 (da) 2014-11-03
DE602004032328D1 (de) 2011-06-01
JP5976288B2 (ja) 2016-08-23
PL2371391T3 (pl) 2015-01-30
HK1208815A1 (en) 2016-03-18
SI1624892T1 (sl) 2011-08-31
FR16C1012I1 (es) 2016-09-12
CY1119353T1 (el) 2018-02-14
KR20060018837A (ko) 2006-03-02
WO2004100898A3 (en) 2005-08-18
DK2853272T3 (da) 2017-11-06
BRPI0410129B8 (pt) 2021-05-25
JP4887152B2 (ja) 2012-02-29
FR16C1012I2 (fr) 2019-01-11
LT2853272T (lt) 2017-10-10
EP1624892B1 (en) 2011-04-20
KR101268707B1 (ko) 2013-05-29
HK1163497A1 (en) 2012-09-14
EP2853272B1 (en) 2017-08-02
EP3275463A1 (en) 2018-01-31
SI2371391T1 (sl) 2014-12-31
DK1624892T3 (da) 2011-08-08
EP2853272A1 (en) 2015-04-01
ES2643289T3 (es) 2017-11-22
JP2007503465A (ja) 2007-02-22
NL300838I2 (es) 2017-01-03
AU2010214661B2 (en) 2012-05-17
US20200031929A1 (en) 2020-01-30
EP1624892A2 (en) 2006-02-15
US10442859B2 (en) 2019-10-15
JP2017019795A (ja) 2017-01-26
CY1115671T1 (el) 2017-01-25
US8133981B2 (en) 2012-03-13
JP2012121878A (ja) 2012-06-28
PT2853272T (pt) 2017-08-30
US8008450B2 (en) 2011-08-30
AU2004238363A1 (en) 2004-11-25
CA2523001C (en) 2013-12-31
US20090238827A1 (en) 2009-09-24
CN1805755A (zh) 2006-07-19
US20090238835A1 (en) 2009-09-24
PL1624892T3 (pl) 2011-09-30
CY1111958T1 (el) 2015-11-04
US20160002335A1 (en) 2016-01-07
PT1624892E (pt) 2011-07-12

Similar Documents

Publication Publication Date Title
US20200031929A1 (en) Therapeutic use of anti-cs1 antibodies
US8349330B2 (en) Therapeutic use of anti-CS1 antibodies
AU2015213401B2 (en) Therapeutic use of anti-CS1 antibodies
AU2012216291B2 (en) Therapeutic use of anti-CS1 antibodies

Legal Events

Date Code Title Description
AS Assignment

Owner name: PROTEIN DESIGN LABS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WILLIAMS, MARNA;TSO, J. YUN;LANDOLFI, NICHOLAS F.;REEL/FRAME:015197/0229;SIGNING DATES FROM 20040827 TO 20040830

AS Assignment

Owner name: PDL BIOPHARMA, INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:PROTEIN DESIGN LABS, INC.;REEL/FRAME:017655/0436

Effective date: 20060109

AS Assignment

Owner name: FACET BIOTECH CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PDL BIOPHARMA, INC.;REEL/FRAME:022326/0412

Effective date: 20090209

AS Assignment

Owner name: PDL BIOPHARMA, NEVADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LIU, GAO;REEL/FRAME:022814/0621

Effective date: 20090523

AS Assignment

Owner name: FACET BIOTECH CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PDL BIOPHARMA, INC.;REEL/FRAME:022843/0548

Effective date: 20090617

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING PUBLICATION PROCESS

AS Assignment

Owner name: ABBVIE BIOTHERAPEUTICS INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:ABBOTT BIOTHERAPEUTICS CORP.;REEL/FRAME:029612/0275

Effective date: 20121126